374 related articles for article (PubMed ID: 12750440)
1. Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain.
Villetti G; Bergamaschi M; Bassani F; Bolzoni PT; Maiorino M; Pietra C; Rondelli I; Chamiot-Clerc P; Simonato M; Barbieri M
J Pharmacol Exp Ther; 2003 Aug; 306(2):804-14. PubMed ID: 12750440
[TBL] [Abstract][Full Text] [Related]
2. CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model.
Mathiesen O; Imbimbo BP; Hilsted KL; Fabbri L; Dahl JB
J Pain; 2006 Aug; 7(8):565-74. PubMed ID: 16885013
[TBL] [Abstract][Full Text] [Related]
3. Potent antihyperalgesic activity without tolerance produced by glycine site antagonist of N-methyl-D-aspartate receptor GV196771A.
Quartaroli M; Carignani C; Dal Forno G; Mugnaini M; Ugolini A; Arban R; Bettelini L; Maraia G; Belardetti F; Reggiani A; Trist DG; Ratti E; Di Fabio R; Corsi M
J Pharmacol Exp Ther; 1999 Jul; 290(1):158-69. PubMed ID: 10381772
[TBL] [Abstract][Full Text] [Related]
4. Effects of (S)-3,4-DCPG, an mGlu8 receptor agonist, on inflammatory and neuropathic pain in mice.
Marabese I; de Novellis V; Palazzo E; Scafuro MA; Vita D; Rossi F; Maione S
Neuropharmacology; 2007 Feb; 52(2):253-62. PubMed ID: 17113112
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of selective NK(1) receptor antagonist CI-1021 in animal models of inflammatory and neuropathic pain.
Gonzalez MI; Field MJ; Hughes J; Singh L
J Pharmacol Exp Ther; 2000 Aug; 294(2):444-50. PubMed ID: 10900217
[TBL] [Abstract][Full Text] [Related]
6. N-antipyrine-3, 4-dichloromaleimide, an effective cyclic imide for the treatment of chronic pain: the role of the glutamatergic system.
Quintão NL; da Silva GF; Antonialli CS; de Campos-Buzzi F; Corrêa R; Filho VC
Anesth Analg; 2010 Mar; 110(3):942-50. PubMed ID: 20185671
[TBL] [Abstract][Full Text] [Related]
7. ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat.
Kowaluk EA; Mikusa J; Wismer CT; Zhu CZ; Schweitzer E; Lynch JJ; Lee CH; Jiang M; Bhagwat SS; Gomtsyan A; McKie J; Cox BF; Polakowski J; Reinhart G; Williams M; Jarvis MF
J Pharmacol Exp Ther; 2000 Dec; 295(3):1165-74. PubMed ID: 11082454
[TBL] [Abstract][Full Text] [Related]
8. CHF3381, a novel antinociceptive agent, attenuates capsaicin-induced pain in rats.
Bassani F; Bergamaschi M; Tonino Bolzoni P; Villetti G
Eur J Pharmacol; 2005 Sep; 519(3):231-6. PubMed ID: 16125167
[TBL] [Abstract][Full Text] [Related]
9. Secondary heat, but not mechanical, hyperalgesia induced by subcutaneous injection of bee venom in the conscious rat: effect of systemic MK-801, a non-competitive NMDA receptor antagonist.
Chen HS; Chen J
Eur J Pain; 2000; 4(4):389-401. PubMed ID: 11124011
[TBL] [Abstract][Full Text] [Related]
10. Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents.
Field MJ; Oles RJ; Lewis AS; McCleary S; Hughes J; Singh L
Br J Pharmacol; 1997 Aug; 121(8):1513-22. PubMed ID: 9283683
[TBL] [Abstract][Full Text] [Related]
11. Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain.
Medvedev IO; Malyshkin AA; Belozertseva IV; Sukhotina IA; Sevostianova NY; Aliev K; Zvartau EE; Parsons CG; Danysz W; Bespalov AY
Neuropharmacology; 2004 Aug; 47(2):175-83. PubMed ID: 15223296
[TBL] [Abstract][Full Text] [Related]
12. An antisense oligonucleotide to the N-methyl-D-aspartate (NMDA) subunit NMDAR1 attenuates NMDA-induced nociception, hyperalgesia, and morphine tolerance.
Shimoyama N; Shimoyama M; Davis AM; Monaghan DT; Inturrisi CE
J Pharmacol Exp Ther; 2005 Feb; 312(2):834-40. PubMed ID: 15388787
[TBL] [Abstract][Full Text] [Related]
13. Role of the spinal cord NR2B-containing NMDA receptors in the development of neuropathic pain.
Qu XX; Cai J; Li MJ; Chi YN; Liao FF; Liu FY; Wan Y; Han JS; Xing GG
Exp Neurol; 2009 Feb; 215(2):298-307. PubMed ID: 19046970
[TBL] [Abstract][Full Text] [Related]
14. Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain.
Chen SR; Samoriski G; Pan HL
Neuropharmacology; 2009 Aug; 57(2):121-6. PubMed ID: 19422840
[TBL] [Abstract][Full Text] [Related]
15. Treatment of a chronic allodynia-like response in spinally injured rats: effects of systemically administered excitatory amino acid receptor antagonists.
Hao JX; Xu XJ
Pain; 1996 Aug; 66(2-3):279-85. PubMed ID: 8880851
[TBL] [Abstract][Full Text] [Related]
16. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain.
Schiene K; De Vry J; Tzschentke TM
J Pharmacol Exp Ther; 2011 Nov; 339(2):537-44. PubMed ID: 21816956
[TBL] [Abstract][Full Text] [Related]
17. Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy.
Beyreuther B; Callizot N; Stöhr T
Eur J Pharmacol; 2006 Jun; 539(1-2):64-70. PubMed ID: 16682022
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of CHF3381 as a novel antiepileptic agent.
Villetti G; Bregola G; Bassani F; Bergamaschi M; Rondelli I; Pietra C; Simonato M
Neuropharmacology; 2001 Jun; 40(7):866-78. PubMed ID: 11378157
[TBL] [Abstract][Full Text] [Related]
19. Intrathecal injection of the sigma(1) receptor antagonist BD1047 blocks both mechanical allodynia and increases in spinal NR1 expression during the induction phase of rodent neuropathic pain.
Roh DH; Kim HW; Yoon SY; Seo HS; Kwon YB; Kim KW; Han HJ; Beitz AJ; Na HS; Lee JH
Anesthesiology; 2008 Nov; 109(5):879-89. PubMed ID: 18946301
[TBL] [Abstract][Full Text] [Related]
20. Lacosamide displays potent antinociceptive effects in animal models for inflammatory pain.
Stöhr T; Krause E; Selve N
Eur J Pain; 2006 Apr; 10(3):241-9. PubMed ID: 15946870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
